Progress Report The ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudy of InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useof tumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease

Mario Cottone, Fernando Rizzello, Claudio Papi, Alessandro Armuzzi, Aurora Bortoli, Renata D'Incà, Fabiana Castiglione, Sandro Ardizzone, Paolo Gionchetti, Vito Annese, Anna Kohn, Maurizio Vecchi, Livia Biancone, Gilberto Poggioli

Risultato della ricerca: Article

106 Citazioni (Scopus)

Abstract

Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon- sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse. Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisation have publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces- sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.Forthesereasonsthe Italian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDisease have decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease. The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistant disease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependent and refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistant active UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy; special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinical experience ofanationalworkinggroup.
Lingua originaleEnglish
pagine (da-a)1-20
Numero di pagine21
RivistaDigestive and Liver Disease
Volume43
Stato di pubblicazionePublished - 2011

All Science Journal Classification (ASJC) codes

  • Hepatology
  • Gastroenterology

Cita questo

Progress Report The ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudy of InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useof tumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease. / Cottone, Mario; Rizzello, Fernando; Papi, Claudio; Armuzzi, Alessandro; Bortoli, Aurora; D'Incà, Renata; Castiglione, Fabiana; Ardizzone, Sandro; Gionchetti, Paolo; Annese, Vito; Kohn, Anna; Vecchi, Maurizio; Biancone, Livia; Poggioli, Gilberto.

In: Digestive and Liver Disease, Vol. 43, 2011, pag. 1-20.

Risultato della ricerca: Article

Cottone, M, Rizzello, F, Papi, C, Armuzzi, A, Bortoli, A, D'Incà, R, Castiglione, F, Ardizzone, S, Gionchetti, P, Annese, V, Kohn, A, Vecchi, M, Biancone, L & Poggioli, G 2011, 'Progress Report The ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudy of InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useof tumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease', Digestive and Liver Disease, vol. 43, pagg. 1-20.
Cottone, Mario ; Rizzello, Fernando ; Papi, Claudio ; Armuzzi, Alessandro ; Bortoli, Aurora ; D'Incà, Renata ; Castiglione, Fabiana ; Ardizzone, Sandro ; Gionchetti, Paolo ; Annese, Vito ; Kohn, Anna ; Vecchi, Maurizio ; Biancone, Livia ; Poggioli, Gilberto. / Progress Report The ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudy of InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useof tumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease. In: Digestive and Liver Disease. 2011 ; Vol. 43. pagg. 1-20.
@article{70e9c0fa45d94f0b9f00ddd3a1d5b87a,
title = "Progress Report The ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudy of InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useof tumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease",
abstract = "Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon- sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse. Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisation have publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces- sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.Forthesereasonsthe Italian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDisease have decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease. The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistant disease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependent and refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistant active UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy; special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinical experience ofanationalworkinggroup.",
keywords = "Guidelines.Biologics.Inflammatory bowel disease.",
author = "Mario Cottone and Fernando Rizzello and Claudio Papi and Alessandro Armuzzi and Aurora Bortoli and Renata D'Inc{\`a} and Fabiana Castiglione and Sandro Ardizzone and Paolo Gionchetti and Vito Annese and Anna Kohn and Maurizio Vecchi and Livia Biancone and Gilberto Poggioli",
year = "2011",
language = "English",
volume = "43",
pages = "1--20",
journal = "Digestive and Liver Disease",
issn = "1590-8658",
publisher = "Elsevier",

}

TY - JOUR

T1 - Progress Report The ItalianSocietyofGastroenterology(SIGE)andtheItalianGroupforthestudy of InflammatoryBowelDisease(IG-IBD)ClinicalPracticeGuidelines:The useof tumor necrosisfactor-alphaantagonisttherapyinInflammatoryBowelDisease

AU - Cottone, Mario

AU - Rizzello, Fernando

AU - Papi, Claudio

AU - Armuzzi, Alessandro

AU - Bortoli, Aurora

AU - D'Incà, Renata

AU - Castiglione, Fabiana

AU - Ardizzone, Sandro

AU - Gionchetti, Paolo

AU - Annese, Vito

AU - Kohn, Anna

AU - Vecchi, Maurizio

AU - Biancone, Livia

AU - Poggioli, Gilberto

PY - 2011

Y1 - 2011

N2 - Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon- sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse. Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisation have publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces- sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.Forthesereasonsthe Italian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDisease have decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease. The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistant disease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependent and refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistant active UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy; special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinical experience ofanationalworkinggroup.

AB - Biological therapiesareanimportantstepinthemanagementofInflammatoryBowelDiseases.Incon- sideration ofhighcostandsafetyissuesthereistheneedtohaveclearrecommendationsfortheiruse. Despite theAmericanGastroenterologicalAssociationandtheEuropeanCrohn’sandColitisOrganisation have publishedexhaustiveInflammatoryBowelDiseaseguidelines,nationalguidelinesmaybeneces- sary asculturalvalues,economicalandlegalissuesmaydifferbetweencountries.Forthesereasonsthe Italian SocietyofGastroenterologyandtheItalianGroupforthestudyofInflammatoryBowelDisease have decidedtoelaboratetheItalianguidelinesontheuseofbiologicsinInflammatoryBowelDisease. The followingitemshavebeenchosen:definitionsofactive,inactive,steroiddependentandresistant disease; measuresofactivity;anti-tumornecrosisfactoralphatherapyuseinactivesteroiddependent and refractoryluminalCrohn’sDisease,infistulisingCrohn’sDisease,insteroiddependentandresistant active UlcerativeColitis;riskofcancer;riskofinfectionsduringanti-tumornecrosisfactoralphatherapy; special situations.Theseguidelinesarebasedonevidencefromrelevantmedicalliteratureandclinical experience ofanationalworkinggroup.

KW - Guidelines.Biologics.Inflammatory bowel disease.

UR - http://hdl.handle.net/10447/53766

M3 - Article

VL - 43

SP - 1

EP - 20

JO - Digestive and Liver Disease

JF - Digestive and Liver Disease

SN - 1590-8658

ER -